NOVELSTEM Share Price OTC Markets

NSTM

US4362331005

Biotechnology & Medical Research

Delayed OTC Markets 08:29:07 05/10/2021 pm IST			5-day change	1st Jan Change
0.2700 ^USD	+7.57%		-3.50%	+44.75%

14/08	NovelStem International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
15/05	NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

NovelStem International Corp. is a development stage biotechnology holding company focused on stem cell-based technology. The Company's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patientsâ€™ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	5L 4L 4L 4L 7L 4.53Cr 7L 46.95L 18.34L 2.31Cr 17.59L 17.21L 7.41Cr	P/E 2024	-0.11x	P/E 2025	0.18x
Enterprise Value	23.72L 21.2L 19.77L 17.96L 33.83L 23Cr 34.08L 2.38Cr 92.84L 12Cr 89.05L 87.13L 38Cr	EV / Sales 2024	39,81,32,333x	EV / Sales 2025	-
Free-Float	38.73%	Yield 2024 *	-	Yield 2025	-

14/08	NovelStem International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
15/05	NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
26/03	NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
26/03	NovelStem International Corp. Auditor Raises 'Going Concern' Doubt	CI
13/11	NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
07/25/07	NovelStem International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
20/25/20	NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
08/25/08	NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
07/25/07	NovelStem International Corp. Auditor Raises 'Going Concern' Doubt	CI
15/24/15	NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
15/24/15	NovelStem International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
16/24/16	NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02/24/02	NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

20/25/20	NovelStem Announces Material Developments and Strategic Repositioning of the Company	AQ
01/23/01	NOVELSTEM INTERNATIONAL CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
18/23/18	NOVELSTEM INTERNATIONAL CORP. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
15/22/15	NOVELSTEM INTERNATIONAL CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
04/22/04	NOVELSTEM INTERNATIONAL CORP. : Change in Directors or Principal Officers (form 8-K)	AQ

Manager	Title	Age	Since
Christine Jenkins DFI	Director of Finance/CFO	63	29/09/2022
Jan Loeb PSD	President	67	13/01/2023

Director	Title	Age	Since
Mitchell Rubenstein CHM	Chairman	72	22/01/1993
Jan Loeb CHM	Chairman	67	01/07/2018
Eric Richman BRD	Director/Board Member	65	01/06/2018

NOVELSTEM Share Price OTC Markets

Stocks

NSTM

US4362331005

Biotechnology & Medical Research

Valuation: NOVELSTEM

Latest news: NOVELSTEM

Press Releases: NOVELSTEM

Quotes and Performance

Managers and Directors: NOVELSTEM

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NOVELSTEM	+7.57%	-3.50%	-	-	5L
WUXI APPTEC CO., LTD.	+4.16%	+4.16%	+49.37%	+94.17%	7.47TCr
ARGENX SE	+0.46%	-0.97%	+23.51%	+79.34%	5.87TCr
LONZA GROUP AG	+0.17%	+0.35%	+6.85%	+34.55%	4.84TCr
REVOLUTION MEDICINES, INC.	+0.50%	-2.14%	+331.33%	+702.20%	4.31TCr
IQVIA HOLDINGS INC.	-0.72%	-3.99%	+28.50%	+29.94%	4.25TCr
BEONE MEDICINES AG	+0.34%	-0.52%	+6.56%	+109.35%	4.14TCr
CELLTRION, INC.	-0.11%	+1.96%	+9.19%	+52.66%	3.13TCr
BIONTECH SE	-0.50%	-3.10%	-10.19%	-14.35%	2.39TCr
INSMED INCORPORATED	-3.32%	-10.86%	-37.32%	+316.28%	2.22TCr
Average	+0.86%	-2.37%	+45.31%	+156.02%	4.29TCr
Weighted average by Cap.	+0.68%	-1.78%	+52.73%	+149.50%

	2024	2025
Net sales	0.01 0.01 0.01 0.01 0.02 1.16 0.02 0.12 0.05 0.59 0.05 0.04 1.9	-
Net income	-32.33L -28.89L -26.95L -24.48L -46.1L -31Cr -46.45L -3.24Cr -1.27Cr -16Cr -1.21Cr -1.19Cr -51Cr	23.8L 21.26L 19.84L 18.02L 33.94L 23Cr 34.19L 2.38Cr 93.14L 12Cr 89.35L 87.41L 38Cr
Net Debt	44.12L 39.42L 36.78L 33.41L 62.92L 43Cr 63.39L 4.42Cr 1.73Cr 22Cr 1.66Cr 1.62Cr 70Cr	19.03L 17.01L 15.87L 14.41L 27.14L 18Cr 27.35L 1.91Cr 74.49L 9.36Cr 71.46L 69.91L 30Cr